GLY-230 is under clinical development by Glycadia and currently in Phase I for Diabetic Retinopathy. According to GlobalData, Phase I drugs for Diabetic Retinopathy have a 79% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how GLY-230’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
GLY-230 is under development for the treatment of diabetic nephropathy,diabetic retinopathy and diabetic neuropathy, diabetic macrovascular disease and Alzheimer's disease The drug candidate is administered through oral route. It is selective glycation inhibitor. It is a new chemical entity (NCE).
For a complete picture of GLY-230’s drug-specific PTSR and LoA scores, buy the report here.